Status and phase
Conditions
Treatments
About
An open-label, randomized, single-dose, oral administration, 2-sequence, 2- period, crossover study to evaluate bioequivalence between YHP2305 and YHR2404 in healthy subjects
Full description
Subjects in group A will be administered comparator and YHP2305 by crossover design on day 1, 8.
Subjects in group B will be administered YHP2305 and comparator by crossover design on day 1, 8.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
34 participants in 2 patient groups
Loading...
Central trial contact
Jinhyun Choi
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal